4-AcO-MET Facts
Psychedelic;
Description
4-AcO-MET (4-acetoxy-N-methyl-N-ethyltryptamine) — metacetin — is a synthetic psychedelic of the tryptamine class. It activates serotonin receptors in the brain, producing the visual and cognitive shifts characteristic of classical psychedelics.[1]
Subjective effects include geometric visual patterns, color enhancement, time alteration, elevated mood, and heightened emotional sensitivity. The experience is warm and visually rich — lighter than psilocybin, with a playful, aesthetic character that favors immersion over introspection.
4-AcO-MET produces no physical dependence, and no lethal dose has been established in any species.[2] The primary risks are psychological — panic, prolonged distress, or psychotic episodes — amplified by combining with MAOIs or tramadol, which can trigger a life-threatening serotonin overload.[3]
Dose and durationby route · individual sensitivity varies
Starts in 20 – 60 minLasts 4 – 6 hoursAfter-effects 2 – 4 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 7 days
- Carries over to
- psilocybin;
psilocin; LSD; DMT; mescaline; 4-AcO-DMT; 4-HO-MiPT
Effectslikely at a common dose
- Perception
- Color enhancement;
Visual drifting; Color alteration; Tracers; Music enhancement; Geometry; Visual breathing; +23 possible, including Visual haze / noise, Spatial disorientation, Vestibular distortion - Body
- Pupil dilation;
Spontaneous body sensations; Body high; +22 possible, including Heart rate perception changes, Insomnia, Motor control impairment - Thinking
- Novelty enhancement;
Aesthetic enhancement; Introspection enhancement; +24 possible, including Cognitive impairment, Memory suppression, Decision impairment - Feeling
- Emotional enhancement;
Euphoria; +6 possible, including Emotional lability, Anxiety - Self
- none likely · 7 possible, including Derealization, Depersonalization
- Time
- Time alteration;
+2 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 3 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^McKenna DJ, Repke DB, Lo L, Peroutka SJ (1990) Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes — Neuropharmacology PMID:2139186
- [2]^Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science — Journal of Psychopharmacology doi:10.1177/02698811211069100
- [3]^MacCallum CA, Lo LA, Pistawka CA, Deol JK (2022) Therapeutic use of psilocybin: Practical considerations for dosing and administration — Frontiers in Psychiatry doi:10.3389/fpsyt.2022.1040217